Joshua Grass, Escient Pharma CEO

San Diego biotech lands $120M to launch a slate of tri­als in neu­rosen­so­ry dis­or­ders

Days af­ter adding some fi­nance, deal­mak­ing and tech­ni­cal tal­ent to the top team, Escient Phar­ma has tak­en the wraps off a $120 mil­lion round to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.